INMB Inmune Bio, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Inmune Bio, Inc. (INMB) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 30, 2026, a 10-Q quarterly report filed on October 30, 2025, an 8-K current report filed on February 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Inmune Bio, Inc. (INMB) (SEC CIK 1711754), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 7.01: Regulation FD Disclosure
- • Inmune Bio filed a Reg FD disclosure (Item 7.01), signaling material non-public information is being broadly released to maintain fair market access
- • Filing text contains no substantive disclosed information — full content likely resides in an accompanying exhibit (e.g., Exhibit 99.1)
Item 8.01: Other Events
- • Webinar Feb 27, 2026 at 9:30 a.m. ET covering XPro1595 registrational pathway for early Alzheimer's disease
- • Registrational pathway detail signals INMB advancing toward pivotal trial or FDA approval strategy for XPro™
Annual Reports Archive10-K
AI-powered analysis of Inmune Bio, Inc. (INMB) 10-K annual reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Inmune Bio, Inc. (INMB) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $374K | $155K | $14K | $50K |
| Operating Income | -$26.0M | -$29.7M | -$42.6M | -$47.4M |
| Net Income | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Op. Margin | -6938.8% | -19187.7% | -304535.7% | -94766.0% |
| Net Margin | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| Balance Sheet | ||||
| Total Assets | $81.8M | $57.0M | $39.6M | $32.4M |
| Equity | $60.1M | $37.3M | $32.1M | $23.5M |
| ROE | -45.4% | -80.4% | -131.1% | -195.3% |
Source: XBRL financial data from Inmune Bio, Inc. (INMB) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
10-K | Mar 30, 2026 | Dec 31, 2025 | — | |
8-K | Feb 27, 2026 | — | Analysis | — |
8-K | Feb 23, 2026 | — | Analysis | — |
8-K | Feb 19, 2026 | — | — | |
8-K | Feb 13, 2026 | — | — | |
8-K | Jan 27, 2026 | — | — | |
8-K | Dec 23, 2025 | — | — | |
8-K | Dec 19, 2025 | — | — | |
8-K | Dec 10, 2025 | — | — | |
8-K | Dec 8, 2025 | — | — | |
8-K | Dec 5, 2025 | — | — | |
8-K | Dec 3, 2025 | — | — | |
8-K | Nov 28, 2025 | — | — | |
10-Q | Oct 30, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Mar 27, 2025 | Dec 31, 2024 | Analysis | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-K | Mar 28, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 1, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 3, 2023 | Mar 31, 2023 | — | |
10-K | Mar 2, 2023 | Dec 31, 2022 | — |
Frequently Asked Questions
What are the latest INMB SEC filings in 2026?
Inmune Bio, Inc. (INMB) has filed a 10-K annual report on March 30, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on February 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did INMB file its most recent 10-K annual report?
Inmune Bio, Inc. (INMB) filed its most recent 10-K annual report on March 30, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view INMB 10-Q quarterly reports?
Inmune Bio, Inc. (INMB)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every INMB 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has INMB filed recently?
Inmune Bio, Inc. (INMB)'s most recent 8-K was filed on February 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find INMB insider trading activity (Form 4)?
SignalX aggregates every INMB Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does INMB file with the SEC?
Inmune Bio, Inc. (INMB) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INMB filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Inmune Bio, Inc. (INMB).
What is INMB's SEC CIK number?
Inmune Bio, Inc. (INMB)'s SEC CIK (Central Index Key) number is 1711754. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1711754 to look up all INMB filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find INMB return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Inmune Bio, Inc. (INMB) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Inmune Bio, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 41+ filings.